- Home
- SPRO vs ESP Comparison
SPRO vs ESP Comparison
Compare SPRO & ESP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- ESP
- Stock Information
- Founded
- SPRO 2013
- ESP 1928
- Country
- SPRO United States
- ESP United States
- Employees
- SPRO N/A
- ESP N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- ESP Industrial Machinery/Components
- Sector
- SPRO Health Care
- ESP Technology
- Exchange
- SPRO Nasdaq
- ESP Nasdaq
- Market Cap
- SPRO 128.9M
- ESP 148.8M
- IPO Year
- SPRO 2017
- ESP N/A
- Fundamental
- Price
- SPRO $2.33
- ESP $39.00
- Analyst Decision
- SPRO Buy
- ESP
- Analyst Count
- SPRO 4
- ESP 0
- Target Price
- SPRO $5.00
- ESP N/A
- AVG Volume (30 Days)
- SPRO 1.2M
- ESP 18.7K
- Earning Date
- SPRO 11-13-2025
- ESP 09-26-2025
- Dividend Yield
- SPRO N/A
- ESP 2.56%
- EPS Growth
- SPRO N/A
- ESP 31.88
- EPS
- SPRO N/A
- ESP 3.02
- Revenue
- SPRO $48,576,000.00
- ESP $43,950,872.00
- Revenue This Year
- SPRO N/A
- ESP N/A
- Revenue Next Year
- SPRO N/A
- ESP N/A
- P/E Ratio
- SPRO N/A
- ESP $12.51
- Revenue Growth
- SPRO N/A
- ESP 13.46
- 52 Week Low
- SPRO $0.51
- ESP $24.85
- 52 Week High
- SPRO $3.22
- ESP $55.00
- Technical
- Relative Strength Index (RSI)
- SPRO 56.08
- ESP 48.29
- Support Level
- SPRO $2.16
- ESP $36.00
- Resistance Level
- SPRO $2.42
- ESP $39.48
- Average True Range (ATR)
- SPRO 0.12
- ESP 1.68
- MACD
- SPRO -0.00
- ESP 0.46
- Stochastic Oscillator
- SPRO 46.85
- ESP 76.14
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.